Evidence map›Paper›PMID 31831073›Full record

ArticleTrials2019

Protocol for a partially nested randomized controlled trial to evaluate the effectiveness of the Scleroderma Patient-centered Intervention Network Support Group Leader EDucation (SPIN-SSLED) Program.

Brett D Thombs, Kylene Aguila, Laura Dyas, Marie-Eve Carrier, Claire Fedoruk, Linda Horwood, Mara Cañedo-Ayala, Maureen Sauvé, Linda Kwakkenbos, Vanessa L Malcarne and 6 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03965780 (The Scleroderma Patient-centered Intervention Network - Scleroderma Support Group Leader EDucation Program Trial), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03965780 nacompletednot on this map

The Scleroderma Patient-centered Intervention Network - Scleroderma Support Group Leader EDucation Program Trial (SPIN-SSLED)

TypeinterventionalSponsorLady Davis InstituteRan2019 to 2021Enrolled148ConditionsScleroderma, SystemicArmsSPIN-SSLED Program
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Brett D ThombsLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada. brett.thombs@mcgill.ca.ORCID http://orcid.org/0000-0002-5644-8432
Kylene AguilaLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Laura DyasScleroderma Foundation Michigan Chapter, Southfield, MI, USA.
Marie-Eve CarrierLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Claire FedorukLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Linda HorwoodLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Mara Cañedo-AyalaLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Maureen SauvéScleroderma Society of Ontario and Scleroderma Canada, Hamilton, ON, Canada.
Linda KwakkenbosDepartment of Clinical Psychology, Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands.
Vanessa L MalcarneDepartment of Psychology, San Diego State University, California, USA.
Ghassan El-BaalbakiDepartment of Psychology, Université du Québec à Montréal, Montreal, QC, Canada.
Sandra PeláezLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Kerri ConnollyScleroderma Foundation, Danvers, MA, USA.
Marie HudsonLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Robert W PlattLady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
SPIN-SSLED Support Group Advisory Team
Jewish General Hospital · CARadboud University Nijmegen · NLUniversité du Québec à Montréal · CAMcGill University Health Centre · CAMultiple Sclerosis Society of Canada · CA

Funding

CIHR PJT-162126Mitacs IT1356Scleroderma Society of Ontario N/A
6 · The paper itself

Abstract

backgroundSome people with rare diseases rely on peer-led support groups for disease-specific education and emotional and practical support. Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune connective tissue disease. Many people with SSc cannot access support groups, and, when support groups exist, they may not be sustained due to challenges that could be addressed via leader training. The Scleroderma Patient-centered Intervention Network (SPIN), along with SSc patient organization partners, developed a training program for SSc patient support group leaders, the Scleroderma Support group Leader EDucation (SPIN-SSLED) Program. We recently completed a feasibility trial in which we successfully delivered the program to two groups of support group leaders who reported a high level of satisfaction with the program and its delivery. The primary objective of the full-scale SPIN-SSLED trial is to evaluate the effect of the program on support group leaders' self-efficacy for carrying out their leadership role. Secondary objectives include evaluating effects on leader burnout, leader satisfaction (participation efficacy), and emotional distress. METHODS/

designThe SPIN-SSLED trial is a pragmatic randomized controlled trial (RCT) in which 180 support group leaders will be randomly allocated to training groups of 6 participants each or to a waitlist control. We will use a partially nested RCT design to reflect dependence between individuals in training groups, but not in the waitlist control. Participants allocated to the training program will receive the 13-module SPIN-SSLED Program, delivered via webinar over the course of 3 months in weekly 60-90-min sessions. The primary outcome is leader self-efficacy, measured by the Scleroderma Support Group Leader Self-efficacy Scale post-intervention. Secondary outcomes are leader self-efficacy at 3 months post-intervention, and leader burnout, volunteer job satisfaction (participation efficacy), and emotional distress post-intervention and at 3 months post-intervention. DISCUSSION: The SPIN-SSLED trial will test whether a training program for SSc patient support group leaders increases the self-efficacy of group leaders to carry out leadership tasks. The program has the potential to significantly improve the effectiveness and sustainability of existing SSc support groups, to increase the number of available support groups, and to be adapted for other chronic diseases.

trial registrationClinicalTrials.gov, NCT03965780. Registered on 29 May 2019.

Indexed as

LeadershipSelf EfficacyBurnout, PsychologicalEducation, ContinuingHumansPatient Education as TopicPeer GroupPersonal SatisfactionPragmatic Clinical Trials as TopicPsychological DistressRandomized Controlled Trials as TopicScleroderma, SystemicSelf-Help GroupsFeasibility trialPatient educationPeer supportSclerodermaSupport groupsSystemic sclerosis

Identifiers

PMID31831073
PMCPMC6909446
OpenAlexW2995888495

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.